Eli Lilly said its experimental gene therapy restored hearing in a boy born with profound hearing loss. The results for this experimental treatment come three months after Regeneron Pharmaceuticals reported early but encouraging data for its hearing loss gene therapy.
Eli Lilly is acquiring Akouos on the heels of the biotech receiving FDA permission to begin a clinical trial testing its gene therapy for an inherited form of hearing loss. The deal is Lilly’s second gene therapy acquisition following the 2021 buyout of Prevail Therapeutics.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.